Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Liberando el potencial de movimiento: mejorando el tratamiento de la enfermedad de Parkinson con EksoSkeleton robótico

28 de septiembre de 2026 actualizado por: Jacqueline Brown, Albert Einstein Healthcare Network

Utilización de EksoSkeleton robótico para lograr altas dosis, intensidad y complejidad de la marcha en el tratamiento de personas con enfermedad de Parkinson

The goal of this study is to see how well therapy with the Eksobionic Exoskeleton (Esko) works for people with Parkinson's disease (PWPD). Esko is a robotic device that provides high repetition and intensity training. The investigators will examine its impact on walking, balance, and quality of life before, during and after an eight-week intervention program. The results will lay the groundwork for future trials, potentially leading to long-term improvements in mobility and quality of life for PWPD.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

The study will enroll up to 24 participants with idiopathic Parkinson's disease (PD) and gait or balance impairment, ranging from Hoehn and Yahr stage 1-4. The overall study design consists of an initial assessment followed by physical therapy treatment utilizing the Ekso robotic device. The treatment will take place two times per week for eight weeks, with outcome measures performed during the evaluation, re-evaluation on visit 9, last session, and on a 3 month follow up. Each treatment session will last 60 minutes, divided into set-up, three 15-minute segments, and a wrap-up.

Throughout the treatment sessions, Ekso settings will be adjusted as the patient progresses or fatigues with the device providing optimal levels of support. In brief, each session will begin by establishing an appropriate trajectory or path for each leg, programmed into the Ekso. The Ekso skeleton will assist the participant through this trajectory, gradually reducing assistance as the participant improves. A ceiling for the maximal level of assistance will be set once the participant requires less than 70% assistance on their best step. As the participant progresses and reaches set goals, the trajectory will be removed, and the participant will walk with self-generated movement. The therapist may add resistance or assistance in the direction of the participant's self-generated movement, depending on the patient's fatigue or weakness.

Intensity assessment, as outlined in Aim 2, will involve the utilization of the Rating of Perceived Exertion (RPE) scale and continuous monitoring of the participant's heart rate (HR). The participant will provide an RPE score at the end of each 15-minute segment to indicate the perceived challenge level. HR will be continuously monitored using a Polar arm HR monitor and app, documenting the duration of time spent within different HR zones. As is typical practice in physical therapy, sessions will be interrupted or discontinued if the patient is unable to tolerate further treatment as assessed by the physical therapist.

To evaluate the effects of Ekso-facilitated training on various outcome measures, as stated in Aim 3, several assessments will be performed. These include the 10-Meter Walk Test (10MWT) and 6-Minute Walk Test (6MWT) for gait speed and endurance, the Functional Gait Assessment (FGA) and Timed Up and Go (TUG) for balance and fall risk, the 5 Times Sit-to-Stand (5xSTS) for functional strength and power, and the WHOQOL-BREF questionnaire for quality of life. The time of the last dose of Parkinson's medications will also be noted during each assessment.

The research design and procedures involve a structured treatment protocol utilizing the Ekso, intensity assessment through RPE and HR monitoring, and evaluation of various outcome measures related to gait, balance, strength, and quality of life. This comprehensive approach aims to investigate the effects of Ekso-mediated treatment on functional changes and provide valuable insights into the potential benefits for individuals with Parkinson's disease.

The project endpoints will be reached when all the data required for the study has been collected. However, the study may be terminated prematurely if it is found that over 50% of the participants are unable to tolerate the device or the intensity of the treatment. All participants are fully informed of their right to withdraw from the study at any time if the participant chooses. Participants may also be withdrawn from the study if the participant displays inconsistent attendance to therapy sessions or are unable to tolerate the required level of exercise as indicated by the Rating of Perceived Exertion (RPE). Additionally, any significant changes in the participant's medical status will result in their withdrawal.

The anticipated risks associated with the study are minimal and include fatigue and frustration. Participants experiencing fatigue or frustration will be instructed to take rest breaks as needed. Another potential risk is discomfort during movement assistance. Participants will be encouraged to communicate any areas of discomfort to the therapist, and appropriate modification will be made to the device.

Regarding the risk of loss of confidentiality, precautions will be implemented to ensure the appropriate collection, management, and storage of personal data. These measures are put in place to minimize the risk of unauthorized access or disclosure of participant information. There are no additional known social, legal, or economic risks associated with participation in these studies, further ensuring the safety and well-being of the participants.

Tipo de estudio

Intervencionista

Inscripción (Actual)

13

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Pennsylvania
      • Elkins Park, Pennsylvania, Estados Unidos, 19027
        • Jefferson Moss-Magee Rehabilitation - Elkins Park

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Physician diagnosed idiopathic Parkinson's disease
  2. All Hoehn and Yahr (H&Y) stages will be eligible for inclusion in the study
  3. Able to consent to participation in the research study
  4. Pt agreeable to participate in 45-60 minutes of high intensity (RPE 14-17 for 30 minutes) gait training/ physical therapy.
  5. Sufficient upper extremity strength to use a front wheeled walker
  6. Pt to have self- reported walking/balance deficits
  7. Age: Over age 18
  8. Must be able to tolerate at least 15 min upright
  9. Weigh 220 pounds (100kg) or less
  10. Approximately between 5'0" and 6'4" tall
  11. Have near normal range of motion in hips, knees, and ankles "Can you stand up and straighten your knees even for just a second?" or "Can you lay flat and straighten your knees so there is no bend in the knee?"

Exclusion Criteria:

  1. Currently involved in another intervention study or physical therapy course of care
  2. Concurrent neurological disease
  3. Leg length discrepancy, self-reported.
  4. Spinal instability
  5. Unresolved deep vein thrombosis
  6. Severe muscular or skeletal pain
  7. Open skin ulcerations on buttocks or other body surfaces in contact with exoskeleton or harness
  8. Pregnancy
  9. Cognitive impairments - unable to follow 2 steps commands and communicate for pain or to stop session
  10. Participant requires the assistance of more than one therapist to transfer safely.
  11. Uncontrolled or severe orthostatic hypotension that limits standing tolerance; defined as sustained, symptomatic drops in systolic and diastolic blood pressure when moving from sitting to standing
  12. Active heterotrophic ossification (HO), hip dysplasia or hip/knee axis abnormalities
  13. Colostomy
  14. History of long bone fractures secondary to osteoporosis
  15. Unable to sustain current medication regimen. Participant reports change in Parkinson's Medication in the past week.
  16. Any reason the therapist may deem as harmful to the participant to enroll or continue in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Ekso mediated gait training

Ekso mediated gait training will take place twice per week for 8 weeks . An Ekso Robotic Eksoskeleton will be used during each treatment session; this device can physically assist leg movements along a customized path or resist or amplify movements the participant makes. Each session will be 60 minutes and will be 3 rounds of 15 minutes of Ekso mediated gait training.

Four (4) study related Assessment sessions will be conducted and include a series of physical tests and a written questionnaire. This will be done at the Evaluation/ 1st visit, then the re-evaluation at visit 9, at discharge or visit 17, and finally at a 3-month follow-up.

During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Steps per session & progression through protocol
Periodo de tiempo: 8 weeks

Our goal is to determine the number of steps per session that can be achieved and the rate of progression through various Ekso modes while applying a standardized treatment protocol during Ekso mediated treatment in PwPD. We establish a treatment protocol for use of the Ekso with PwPD, involving two 45-60-minute sessions per week for eight weeks. We hypothesize that under this protocol, participants will achieve >300 steps per session by the 3rd session and will be able to progress through a series of increasingly challenging training modes by meeting target goals. We will measure the number of sessions required to progress through each step of the training program.

8 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gait speed-10MWT
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on gait speed in PwPD. It is hypothesized that benefits will be seen in the 10 Meter Walk Test (10MWT) noted by improvements in gait speed measured in meters per second.

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)
Gait endurance- 6MWT
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on gait endurance in PwPD It is hypothesized that benefits will be seen in the six-minute walk test (6MWT) noted by improvements in gait endurance. This will be measured in change in meters walked during the six minute walk test.

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)
Dynamic balance
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on dynamic balance in PwPD. It is hypothesized that benefits will be seen in the Functional Gait Assessment (FGA) noted by improvements in dynamic balance. The FGA is measured on an ordinal scale ranging from 0 to 30.

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)
Functional strength- 5xSTS
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on functional strength in PwPD. It is hypothesized that benefits will be seen in the Five time sit to stand (5xSTS) assessment noted by improvements in functional strength. This will be measured by time in seconds.

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)
Quality of Life- WHOQOL-BREF
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on quality of Life in PwPD. It is hypothesized that benefits will be seen in the World Health Organization- Quality of Life Brief (WHOQOL-BREF) noted by improvements in the scaled score (recorded in percentage).

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)
Fall risk
Periodo de tiempo: Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Another goal is to determine the effect of Ekso facilitated training on fall risk in PwPD. It is hypothesized that benefits will be seen by decreased risk of falls noted in an improvement in their Timed-up-and-go (TUG) score. This will be assessed by time in seconds

Baseline, re-evaluation (5 weeks), discharge (8 weeks), follow-up (20 weeks)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Intensity achieved
Periodo de tiempo: 8 weeks

Another goal is to determine the activity intensity level achieved by PwPD using a standardized Ekso-mediated treatment protocol. Intensity is essential for functional change. It is unknown what level of intensity is achieved with the Ekso during treatment of PwPD. We hypothesize that treatment utilizing the Ekso achieves high intensity. For the study we will define high intensity by 14-17/20 Borg Rating of Perceived Exertion (RPE) or target heart rate (HR) 70-85% HR max for at least 30 minutes per session for at least 11 out of 15 therapy sessions. During sessions, HR will be monitored continuously and RPE will be recorded at 15-minute intervals.

8 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jacqueline Brown, DPT, Albert Einstein Healthcare Network

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de junio de 2024

Finalización primaria (Actual)

24 de agosto de 2026

Finalización del estudio (Actual)

24 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

18 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

17 de enero de 2024

Publicado por primera vez (Actual)

26 de enero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Any individual data will be de-identified and shared upon reasonable request

Marco de tiempo para compartir IPD

Relevant information will be available with publication of study results.

Criterios de acceso compartido de IPD

Primary investigator will respond to reasonable requests in the interim.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir